GRAP2

Summary

GRAP2 (GRB2 related adaptor protein 2, HGNC:4563) is a protein-coding gene on chromosome 22q13.1, encoding GRB2-related adapter protein 2 (O75791). Interacts with SLP-76 to regulate NF-AT activation.

This gene encodes a member of the GRB2/Sem5/Drk family. This member is an adaptor-like protein involved in leukocyte-specific protein-tyrosine kinase signaling. Like its related family member, GRB2-related adaptor protein (GRAP), this protein contains an SH2 domain flanked by two SH3 domains. This protein interacts with other proteins, such as GRB2-associated binding protein 1 (GAB1) and the SLP-76 leukocyte protein (LCP2), through its SH3 domains. Multiple alternatively spliced transcript variants encoding distinct isoforms have been found for this gene.

Source: NCBI Gene 9402 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 52 total
• MANE Select transcript: NM_004810

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:4563
Approved symbol	GRAP2
Name	GRB2 related adaptor protein 2
Location	22q13.1
Locus type	gene with protein product
Status	Approved
Aliases	Grf40, GrbX, GRBLG, GADS, Mona
Ensembl gene	ENSG00000100351
Ensembl biotype	protein_coding
OMIM	604518
Entrez	9402

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 4 protein_coding, 3 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000344138, ENST00000407075, ENST00000420971, ENST00000460449, ENST00000461082, ENST00000478445, ENST00000481263, ENST00000861558

RefSeq mRNA: 5 — MANE Select: NM_004810 NM_001291824, NM_001291825, NM_001291826, NM_001291828, NM_004810

CCDS: CCDS13999

Canonical transcript exons

ENST00000344138 — 8 exons

Exon	Start	End
ENSE00000654830	39965990	39966158
ENSE00000654832	39969411	39969533
ENSE00001244839	39968042	39968272
ENSE00001244872	39970905	39973721
ENSE00001488758	39901084	39901330
ENSE00003463883	39955819	39955910
ENSE00003491090	39947093	39947184
ENSE00003543586	39960055	39960174

Expression profiles

Bgee: expression breadth ubiquitous, 159 present calls, max score 97.79.

FANTOM5 (CAGE): breadth broad, TPM avg 9.8865 / max 787.7158, expressed in 329 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
192389	3.3664	154
192385	3.2920	171
192382	1.6544	138
192387	0.4262	79
192386	0.3202	78
192381	0.2438	94
192383	0.2065	85
192384	0.1916	83
192388	0.1438	55
192380	0.0417	25

Top tissues by expression

289 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	97.79	gold quality
mononuclear cell	CL:0000842	97.60	gold quality
leukocyte	CL:0000738	97.37	gold quality
granulocyte	CL:0000094	93.67	gold quality
blood	UBERON:0000178	87.42	gold quality
thymus	UBERON:0002370	82.74	gold quality
lymph node	UBERON:0000029	82.46	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	80.52	gold quality
spleen	UBERON:0002106	79.25	gold quality
colonic epithelium	UBERON:0000397	78.02	gold quality
endometrium epithelium	UBERON:0004811	77.33	gold quality
vermiform appendix	UBERON:0001154	76.94	gold quality
bone marrow cell	CL:0002092	75.20	gold quality
upper lobe of left lung	UBERON:0008952	74.77	gold quality
right lung	UBERON:0002167	74.35	gold quality
frontal pole	UBERON:0002795	74.09	gold quality
paraflocculus	UBERON:0005351	73.95	gold quality
bone marrow	UBERON:0002371	73.81	gold quality
small intestine Peyer’s patch	UBERON:0003454	73.42	gold quality
middle frontal gyrus	UBERON:0002702	73.38	gold quality
gall bladder	UBERON:0002110	73.16	gold quality
upper lobe of lung	UBERON:0008948	73.10	gold quality
mucosa of transverse colon	UBERON:0004991	72.16	gold quality
tibial nerve	UBERON:0001323	71.94	gold quality
small intestine	UBERON:0002108	71.73	gold quality
caecum	UBERON:0001153	71.72	gold quality
mucosa of stomach	UBERON:0001199	70.08	gold quality
rectum	UBERON:0001052	70.07	gold quality
tonsil	UBERON:0002372	70.05	gold quality
secondary oocyte	CL:0000655	67.66	gold quality

Single-cell (SCXA)

Detected in 10 experiment(s), a significant marker in 10.

Experiment	Marker?	Max mean expression
E-CURD-122	yes	23.14
E-MTAB-9221	yes	19.47
E-HCAD-10	yes	16.22
E-MTAB-9067	yes	15.92
E-CURD-112	yes	15.88
E-MTAB-8410	yes	11.36
E-MTAB-10042	yes	8.55
E-MTAB-9801	yes	7.59
E-HCAD-1	yes	7.30
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): SPI1, SPIB

miRNA regulators (miRDB)

85 targeting GRAP2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-6768-5P	99.92	67.36	1942
HSA-MIR-329-3P	99.91	66.56	1234
HSA-MIR-362-3P	99.91	66.38	1267
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-4496	99.88	68.89	2236
HSA-MIR-6857-5P	99.87	65.32	985
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-130B-5P	99.83	68.50	1888
HSA-MIR-204-5P	99.79	71.62	2439
HSA-MIR-211-5P	99.79	71.65	2440
HSA-MIR-323A-3P	99.79	70.30	1739

Literature-anchored findings (GeneRIF, showing 15)

• Upstream open reading frames regulate translation of this protein’s mRNA in megakaryocytes. (PMID:12487779)
• Exogenous expression of GrpL in a GrpL-negative B cell line leads to enhanced antigen receptor-induced extracellular signal-related kinase and p38 mitogen-activated protein kinase phosphorylation. (PMID:12496419)
• AML-1 plays a role in driving Mona protein expression in T and myelomonocytic cells. (PMID:12554803)
• Plays a tissue-specific role as an inhibitor of RET receptor tyrosine kinase mitogenic signaling (PMID:12917638)
• Gads plays a dominant role in CD28-mediated IL-2 promoter activation. (PMID:16818765)
• The integrity of T-cell receptor signaling in vivo is sustained both by strong selection of SLP-76 for the Gads C-SH3 domain and by a capacity to buffer intrinsic crossreactivity. (PMID:17235283)
• Our findings define a pathway involving CD28 binding to Grb-2 and its co-operativity with Vav1 in the regulation of T-cell co-stimulation. (PMID:18295596)
• Consistent Grap-2 expression suggests a specific role for this adaptor in human medullary thyroid carcinoma, while qualitative alterations do not appear to influence RET signaling (PMID:19027225)
• The results show that Bcr-Abl regulates the actin cytoskeleton and non-apoptotic membrane blebbing via a GADS/Slp-76/Nck1 adaptor protein pathway. (PMID:20079431)
• Histidine domain-protein tyrosine phosphatase interacts with Grb2 and GrpL (PMID:21179510)
• GADS mediates lymphoid disease downstream of BCR-ABL through the recruitment of specific signaling intermediates. (PMID:23399893)
• Gads was dispensable for TCR-induced phosphorylation of SLP-76, but was a dose-dependent amplifier of TCR-induced CD69 expression. (PMID:25452106)
• GADS deficient T cells displayed similar levels of T cell receptor -induced SLP-76 and PLC-gamma1 phosphorylation but exhibited substantial decrease in TCR-induced IL-2 and IFN-gamma release. (PMID:25636200)
• Following phosphorylation of the tyrosine, the proteins growth factor receptor-bound protein 2 (Grb2), Grb2-related adaptor downstream of Shc (Gads), and p85 subunit of phosphoinositide 3-kinase may bind to pYMNM (where pY is phosphotyrosine) via their Src homology 2 (SH2) domains, leading to downstream signaling to distinct immune pathways. These three adaptor proteins bind to the same site on CD28 with variable affinity (PMID:27927989)
• These data are consistent with a model in which bivalent recruitment of a GADS/SLP-76 complex is required for costimulation by CD6. (PMID:28289074)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	grap2a	ENSDARG00000006468
danio_rerio	grap2b	ENSDARG00000101169
mus_musculus	Grap2	ENSMUSG00000042351
rattus_norvegicus	Grap2	ENSRNOG00000018316
drosophila_melanogaster	dock	FBGN0010583
caenorhabditis_elegans		WBGENE00006410

Paralogs (9): DAPP1 (ENSG00000070190), NCK2 (ENSG00000071051), SLA2 (ENSG00000101082), GRAP (ENSG00000154016), SLA (ENSG00000155926), NCK1 (ENSG00000158092), GRB2 (ENSG00000177885), GRAPL (ENSG00000189152), SH2D5 (ENSG00000189410)

Protein

Protein identifiers

GRB2-related adapter protein 2 — O75791 (reviewed: O75791)

Alternative names: Adapter protein GRID, GRB-2-like protein, GRBLG, GRBX, Grf40 adapter protein, Growth factor receptor-binding protein, Hematopoietic cell-associated adapter protein GrpL, P38, Protein GADS, SH3-SH2-SH3 adapter Mona

All UniProt accessions (3): O75791, B1AH86, Q6FI14

UniProt curated annotations — full annotation on UniProt →

Function. Interacts with SLP-76 to regulate NF-AT activation. Binds to tyrosine-phosphorylated shc.

Subunit / interactions. Interacts with phosphorylated LIME1 upon TCR activation. Interacts with phosphorylated LAT and LAX1 upon TCR activation. Interacts with SHB. Interacts with PTPN23.

Subcellular location. Nucleus. Cytoplasm. Endosome.

Similarity. Belongs to the GRB2/sem-5/DRK family.

Isoforms (2)

UniProt ID	Names	Canonical?
O75791-1	1	yes
O75791-2	2

RefSeq proteins (5): NP_001278753, NP_001278754, NP_001278755, NP_001278757, NP_004801* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000980	SH2	Domain
IPR001452	SH3_domain	Domain
IPR035646	GRAP2_C_SH3	Domain
IPR036028	SH3-like_dom_sf	Homologous_superfamily
IPR036860	SH2_dom_sf	Homologous_superfamily
IPR043539	Grb2-like	Family

Pfam: PF00017, PF00018

UniProt features (24 total): strand 7, modified residue 5, domain 3, splice variant 2, helix 2, compositionally biased region 2, chain 1, sequence variant 1, region of interest 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
5GJH	X-RAY DIFFRACTION	1.2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O75791-F1	70.78	0.31

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5): 236, 262, 45, 106, 187

Function

Pathways and Gene Ontology

Reactome pathways

8 pathways

ID	Pathway
R-HSA-1433557	Signaling by SCF-KIT
R-HSA-202433	Generation of second messenger molecules
R-HSA-2424491	DAP12 signaling
R-HSA-2871796	FCERI mediated MAPK activation
R-HSA-2871809	FCERI mediated Ca+2 mobilization
R-HSA-389356	Co-stimulation by CD28
R-HSA-9607240	FLT3 Signaling
R-HSA-9680350	Signaling by CSF1 (M-CSF) in myeloid cells

MSigDB gene sets: 190 (showing top): MODULE_92, REACTOME_INNATE_IMMUNE_SYSTEM, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, REACTOME_CO_STIMULATION_BY_CD28, GOBP_CELL_CELL_SIGNALING, OSWALD_HEMATOPOIETIC_STEM_CELL_IN_COLLAGEN_GEL_UP, AML_Q6, HUI_MAPK14_TARGETS_UP, GOBP_RAS_PROTEIN_SIGNAL_TRANSDUCTION, REACTOME_TCR_SIGNALING, GOBP_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION, MODULE_46, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, FOXO4_02

GO Biological Process (4): signal transduction (GO:0007165), Ras protein signal transduction (GO:0007265), cell-cell signaling (GO:0007267), regulation of MAPK cascade (GO:0043408)

GO Molecular Function (2): phosphotyrosine residue binding (GO:0001784), protein binding (GO:0005515)

GO Cellular Component (6): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), endosome (GO:0005768), cytosol (GO:0005829), plasma membrane (GO:0005886)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
Fc epsilon receptor (FCERI) signaling	2
Cytokine Signaling in Immune system	2
Signaling by Receptor Tyrosine Kinases	1
TCR signaling	1
DAP12 interactions	1
Regulation of T cell activation by CD28 family	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
cell communication	2
signaling	2
cellular process	1
regulation of cellular process	1
cellular response to stimulus	1
small GTPase-mediated signal transduction	1
MAPK cascade	1
regulation of intracellular signal transduction	1
protein phosphorylated amino acid binding	1
binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1
endomembrane system	1
cytoplasmic vesicle	1
cytoplasm	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

1566 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GRAP2	LCP2	Q13094	999
GRAP2	PLCG1	P19174	996
GRAP2	VAV1	P15498	984
GRAP2	GRB2	P29354	983
GRAP2	LAT	O43561	980
GRAP2	NCK1	P16333	963
GRAP2	SHC1	P29353	959
GRAP2	ITK	Q08881	949
GRAP2	FYB1	O15117	929
GRAP2	ZAP70	P43403	926
GRAP2	SOS1	Q07889	921
GRAP2	CCNDBP1	O95273	914
GRAP2	CALML6	Q8TD86	896
GRAP2	CALML3	P27482	896
GRAP2	CALML4	Q96GE6	896
GRAP2	CALML5	Q9NZT1	896

IntAct

210 interactions, top by confidence:

A	B	Type	Score
LCP2	GRAP2	psi-mi:“MI:0915”(physical association)	0.980
GRAP2	LCP2	psi-mi:“MI:0915”(physical association)	0.980
LCP2	GRAP2	psi-mi:“MI:2364”(proximity)	0.980

BioGRID (199): GRAP2 (Two-hybrid), SPRY2 (Two-hybrid), GRAP2 (Two-hybrid), GAB2 (Affinity Capture-MS), CDC27 (Affinity Capture-MS), STAMBP (Affinity Capture-MS), TNIP1 (Affinity Capture-MS), ZSCAN21 (Affinity Capture-MS), USP8 (Affinity Capture-MS), ANAPC5 (Affinity Capture-MS), PTPN23 (Affinity Capture-MS), ITCH (Affinity Capture-MS), GAB1 (Affinity Capture-MS), GAREM (Affinity Capture-MS), TRIM68 (Affinity Capture-MS)

ESM2 similar proteins: B2RZ59, F1LYQ8, F1P065, F8VPU2, O14796, O35324, O60880, O75791, O88890, O88900, O89100, O94887, P0CE43, P46108, P46109, P47941, P52735, P59622, P87378, P97369, Q03160, Q04929, Q06AA1, Q13239, Q13322, Q14449, Q15080, Q1RMW5, Q2I6J1, Q3ZBB1, Q45HK4, Q5ICW4, Q5RAB8, Q5U2U2, Q60760, Q60898, Q60992, Q63768, Q64010, Q6P4S2

Diamond homologs: A0JNJ1, A1CEK6, A1DFN5, A2QW93, A4RF61, A6QLK6, A7A261, F1LRS8, O35179, O35964, O43307, O74749, O75791, O75886, O88811, O89100, O93436, P02549, P07751, P09215, P09216, P10830, P13395, P16054, P16086, P16546, P23298, P24723, P28867, P29355, P32793, P34885, P38753, P43603, P53281, P62993, P62994, P70297, P87379, P97306

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
MAP4K1	“down-regulates activity”	GRAP2	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 73 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Constitutive Signaling by Aberrant PI3K in Cancer	5	12.7×	4e-03
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	5	9.7×	6e-03

GO biological processes:

GO term	Partners	Fold	FDR
epidermal growth factor receptor signaling pathway	6	23.2×	1e-04
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	7	8.6×	2e-03
negative regulation of apoptotic process	10	5.4×	2e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

52 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	38
Likely benign	2
Benign	4

Top pathogenic / likely-pathogenic (0)

SpliceAI

1412 predictions. Top by Δscore:

Variant	Effect	Δscore
22:39969531:GGG:G	donor_gain	1.0000
22:39969531:GGGGT:G	donor_loss	1.0000
22:39969532:GGG:G	donor_gain	1.0000
22:39969534:G:GA	donor_loss	1.0000
22:39969535:T:A	donor_loss	1.0000
22:39970903:A:AG	acceptor_gain	1.0000
22:39970904:G:GG	acceptor_gain	1.0000
22:39970904:GC:G	acceptor_gain	1.0000
22:39970904:GCGA:G	acceptor_gain	1.0000
22:39955911:G:GG	donor_gain	0.9900
22:39960049:CCACA:C	acceptor_loss	0.9900
22:39960050:CACA:C	acceptor_loss	0.9900
22:39960051:ACAG:A	acceptor_loss	0.9900
22:39960052:CA:C	acceptor_loss	0.9900
22:39960053:A:AG	acceptor_gain	0.9900
22:39960053:A:AT	acceptor_loss	0.9900
22:39960053:AGAT:A	acceptor_gain	0.9900
22:39960054:G:GA	acceptor_loss	0.9900
22:39960054:G:GG	acceptor_gain	0.9900
22:39960054:GATG:G	acceptor_gain	0.9900
22:39960171:TCAGG:T	donor_loss	0.9900
22:39960172:CAGG:C	donor_loss	0.9900
22:39960173:AG:A	donor_loss	0.9900
22:39960174:GGTA:G	donor_loss	0.9900
22:39960175:GTACT:G	donor_loss	0.9900
22:39960176:T:A	donor_loss	0.9900
22:39965980:T:TA	acceptor_gain	0.9900
22:39965984:CTCCA:C	acceptor_loss	0.9900
22:39965985:TCCA:T	acceptor_loss	0.9900
22:39965986:CCA:C	acceptor_loss	0.9900

AlphaMissense

2188 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
22:39966004:T:A	V102D	1.000
22:39966082:T:C	L128P	1.000
22:39947131:T:C	F9L	0.999
22:39947133:C:A	F9L	0.999
22:39947133:C:G	F9L	0.999
22:39955840:T:A	W34R	0.999
22:39955840:T:C	W34R	0.999
22:39955849:G:C	A37P	0.999
22:39955877:T:A	V46E	0.999
22:39960056:T:A	W58R	0.999
22:39960056:T:C	W58R	0.999
22:39960086:G:C	A68P	0.999
22:39960132:G:C	R83P	0.999
22:39960165:T:A	I94N	0.999
22:39960167:T:C	S95P	0.999
22:39960168:C:A	S95Y	0.999
22:39960168:C:T	S95F	0.999
22:39960171:T:A	V96D	0.999
22:39966010:A:G	H104R	0.999
22:39966011:C:A	H104Q	0.999
22:39966011:C:G	H104Q	0.999
22:39966012:T:C	F105L	0.999
22:39966013:T:C	F105S	0.999
22:39966014:C:A	F105L	0.999
22:39966014:C:G	F105L	0.999
22:39966019:T:A	V107D	0.999
22:39966051:T:A	W118R	0.999
22:39966051:T:C	W118R	0.999
22:39971013:T:A	W308R	0.999
22:39971013:T:C	W308R	0.999

dbSNP variants (sampled 300 via entrez): RS1000001181 (22:39939046 C>A), RS1000121576 (22:39910083 G>C), RS1000177726 (22:39950346 T>C), RS1000228368 (22:39902929 A>G,T), RS1000235966 (22:39947663 A>T), RS1000238583 (22:39965578 A>G), RS1000293494 (22:39896115 A>T), RS1000317165 (22:39915717 G>A,T), RS1000324088 (22:39896507 G>A), RS1000387023 (22:39940896 G>A,C), RS1000411707 (22:39962084 A>G), RS1000459386 (22:39906783 G>A,T), RS1000477695 (22:39953431 A>G), RS1000521111 (22:39948860 T>A), RS1000552458 (22:39906570 A>G)

Disease associations

OMIM: gene MIM:604518 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST005752_107	Systemic lupus erythematosus	5.000000e-08
GCST005951_24	Body mass index	2.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
lasiocarpine	increases expression	1
triphenyl phosphate	affects expression	1
sodium arsenite	increases expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
S-(1,2-dichlorovinyl)cysteine	increases expression, affects cotreatment, decreases expression, affects response to substance	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
Air Pollutants	increases abundance, increases expression	1
Benzo(a)pyrene	affects methylation	1
Dichlorodiphenyl Dichloroethylene	increases expression	1
Demecolcine	decreases expression	1
Dexamethasone	increases expression	1
Diuron	decreases expression	1
Estradiol	affects cotreatment, increases expression	1
Ethyl Methanesulfonate	decreases expression	1
Formaldehyde	decreases expression	1
Lipopolysaccharides	decreases expression, affects response to substance, increases expression, affects cotreatment	1
Methapyrilene	increases methylation	1
Methyl Methanesulfonate	decreases expression	1
Phthalic Acids	increases methylation	1
Triclosan	decreases expression	1
Vincristine	decreases expression	1
Aflatoxin B1	increases methylation	1
Asbestos, Crocidolite	affects expression	1
Particulate Matter	increases expression, increases abundance	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.